Population Screening Market Report 2026

The population screening market size has grown strongly in recent years. It will grow from $31.39 billion in 2025 to $33.58 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to expansion of public health screening initiatives, availability of laboratory testing infrastructure, increased disease awareness programs, growth of diagnostic laboratory networks, adoption of early detection strategies.

The population screening market size is expected to see strong growth in the next few years. It will grow to $44.61 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising investments in precision screening technologies, increasing use of population-level health analytics, expansion of national screening programs, growing integration of digital diagnostics, increasing focus on preventive healthcare models. Major trends in the forecast period include increasing use of genomic screening programs, rising adoption of AI-based risk assessment tools, growing expansion of preventive health screening, integration of advanced diagnostic technologies, enhanced data interpretation capabilities.

The increasing prevalence of cancer is expected to drive the growth of the population screening market going forward. Cancer is a disease in which certain cells in the body grow uncontrollably and can spread to other parts of the body, creating serious health risks. Population screening plays a critical role in identifying cancer at an early stage, which supports timely treatment, improves survival rates, and enhances patient outcomes. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, the number of new cancer cases worldwide is projected to exceed 35 million by 2050, representing a 77% increase compared with an estimated 20 million cases in 2022. Therefore, the rising prevalence of cancer is driving the growth of the population screening market.

Major companies operating in the population screening market are focusing on introducing advanced services such as newborn mass screening to improve early detection and support better health outcomes in infants. Newborn mass screening is a public health initiative in which newborns are tested shortly after birth for a range of genetic, metabolic, hormonal, and functional disorders that may not be evident at birth but can cause severe health complications if untreated. For instance, in May 2024, Shimadzu Techno-Research Inc., a Japan-based contract analysis company and subsidiary of Shimadzu Corporation, launched a new contract service that conducts polymerase chain reaction testing for expanded newborn mass screening. This service screens for conditions such as severe combined immunodeficiency, B-cell deficiency, and spinal muscular atrophy, which affect a small number of newborns but require immediate diagnosis and intervention.

In January 2024, Natera, a US-based biotechnology company, acquired Invitae for an undisclosed amount. Through this acquisition, Natera aims to expand its genetic testing capabilities, particularly in non-invasive prenatal screening and carrier screening, thereby strengthening its population screening service offerings. Invitae is a US-based company specializing in advanced genetic testing solutions, including services designed for large-scale population screening.

Major companies operating in the population screening market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., SYNLAB International GmbH, Quidel Corporation, Bio-Rad Laboratories Inc., Unilabs, Qiagen N.V., Exact Sciences Corporation, ARUP Laboratories Inc., LGC Limited, OPKO Health Inc., Natera Inc., Cerba HealthCare S.A.S, Invitae Corp, Amedes Holding GmbH, Grail, Luminex Corporation, Novogene Co. Ltd., Trinity Biotech, Gene by Gene Ltd., Innova Medical Group Inc., LabPLUS.

North America was the largest region in the population screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the population screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the population screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the population screening market by increasing costs of imported diagnostic devices, imaging equipment, laboratory reagents, and data analytics hardware. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported screening technologies, while Asia-Pacific faces cost pressures on exported diagnostic equipment. These tariffs are increasing screening program budgets and slowing equipment upgrades. However, they are also encouraging local manufacturing of diagnostic tools, regional laboratory expansion, and development of cost-efficient screening technologies.

The population screening market research report is one of a series of new reports that provides population screening market statistics, including population screening industry global market size, regional shares, competitors with a population screening market share, detailed population screening market segments, market trends and opportunities, and any further data you may need to thrive in the population screening industry. This population screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Population screening is the process of evaluating the prevalence of a specific disease or trait across an entire population or a defined subgroup. The primary objective of population screening is to identify individuals who may be at risk of developing a disease, distinguishing it from diagnostic testing, which is used to confirm the presence of a condition.

The main products used in population screening include hardware equipment, testing or laboratory services, and analytics or interpretation solutions. Hardware plays a critical role in population screening by providing the necessary tools and equipment to conduct screening tests, collect data, and support healthcare service delivery. Population screening is conducted for both males and females across age groups including under 15 years, 15 to 65 years, and 65 years and above. These screening activities are carried out by various organizations such as hospitals, research institutes, and diagnostic laboratories.

The population screening market consists of revenues earned by entities by providing services such as next-generation sequencing (NGS) and microarray-based genotyping, imaging tests, mammography screening, colonoscopy screening, cholesterol screening, and blood pressure screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The population screening market also includes sales of smartphone-based biosensors, kits, and chips, which are used in providing population screening services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.